Last update 07 Nov 2024

Amulirafusp alfa

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
IMC-002, IMM 0306
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD47 inhibitors(Cluster of differentiation 47 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neuromyelitis OpticaPhase 2-10 Oct 2024
Systemic Lupus ErythematosusPhase 2
CN
12 Aug 2024
Diffuse Large B-Cell LymphomaPhase 2
CN
07 Jun 2023
Follicular LymphomaPhase 2
CN
07 Jun 2023
Mantle-Cell LymphomaPhase 2
CN
07 Jun 2023
B-Cell LymphomaPhase 2-01 May 2023
CD20 Positive B-Cell Non-Hodgkin LymphomaPhase 2
CN
02 Mar 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
11
iovrnwiyod(pkzlivvmly) = Two DLTs (grade 4 PLT decreased without bleeding) were observed at 2.0 mg/kg IMM0306 + 20 mg Lenalidomide dose level. adymeypmzn (lfwvitdvya )
Positive
15 Sep 2024
Phase 2
16
bdoonikxlw(zzonxalcls) = yqdfwrhlbb ykmjvcpofk (kgvrxcqbpx )
Positive
15 Sep 2024
Phase 1
48
jerherwqye(gsfhubjvtv) = ndjqknvzhz jotzzsedhq (qajyxxabvn )
Positive
24 May 2024
jerherwqye(gsfhubjvtv) = vyzuipkuso jotzzsedhq (qajyxxabvn )
Phase 1
8
tmftkujjtm(lzdcromuyl) = One pt experienced treatment related serious adverse event xmhvovjsvz (aswkajxrgo )
Positive
24 May 2024
Phase 1
48
jpsoynwfyi(pdaqkyxycq) = The most frequent treatment related adverse events (TRAEs) were WBC decreased (66.7%), anemia (64.6%), lymphocyte decreased (58.3%), ANC decreased (47.9%), PLT decreased (45.8%), infusion-related reactions (35.4%) jhsjjmxpvk (lyygqwycxj )
Positive
05 Apr 2024
Phase 1/2
42
trekeovbcs(wdueepyaut) = Three treatment related SAEs were PLT decreased (grade 4), chest pain (grade 2) and diarrhea (grade 3). doykgmqwhk (kugyccsyfd )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free